Astria Therapeutics (ATXS) Cash from Operations: 2013-2024
Historic Cash from Operations for Astria Therapeutics (ATXS) over the last 12 years, with Dec 2024 value amounting to -$81.2 million.
- Astria Therapeutics' Cash from Operations fell 47.47% to -$7.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$26.6 million, marking a year-over-year decrease of 13.23%. This contributed to the annual value of -$81.2 million for FY2024, which is 18.65% down from last year.
- Latest data reveals that Astria Therapeutics reported Cash from Operations of -$81.2 million as of FY2024, which was down 18.65% from -$68.4 million recorded in FY2023.
- In the past 5 years, Astria Therapeutics' Cash from Operations ranged from a high of -$30.2 million in FY2021 and a low of -$81.2 million during FY2024.
- In the last 3 years, Astria Therapeutics' Cash from Operations had a median value of -$68.4 million in 2023 and averaged -$64.4 million.
- As far as peak fluctuations go, Astria Therapeutics' Cash from Operations grew by 7.18% in 2021, and later slumped by 57.23% in 2023.
- Astria Therapeutics' Cash from Operations (Yearly) stood at -$32.5 million in 2020, then climbed by 7.18% to -$30.2 million in 2021, then slumped by 44.38% to -$43.5 million in 2022, then plummeted by 57.23% to -$68.4 million in 2023, then decreased by 18.65% to -$81.2 million in 2024.